Posts by Mourabit Halima

Breast cancer remains the most frequently diagnosed cancer among women worldwide, and the pursuit of novel therapies continues to command global attention. In the setting of HR+/HER2− advanced breast cancer, the introduction of entinostat, a novel histone deacetylase inhibitor (HDACi), marks a significant therapeutic advancement. With a distinctive mechanism of action, entinostat not only extends overall survival (OS) but also demonstrates a favorable safety profile. Its innovative once-weekly dosing schedule enhances treatment convenience and patient adherence. When combined with an aromatase inhibitor, entinostat opens a new chapter in second-line management for patients progressing after CDK4/6 inhibitors, pushing breast cancer treatment toward a more personalized and precision-based era.

Hormone receptor-positive (HR+) breast cancer accounts for approximately 70% of all breast cancer cases and remains the most prevalent subtype. While endocrine therapy continues to serve as the cornerstone of HR+ breast cancer treatment, and CDK4/6 inhibitors (CDK4/6i) have become standard in both early and advanced settings, resistance to therapy remains a formidable clinical challenge. With growing insights into resistance mechanisms, histone deacetylase inhibitors (HDACi) have emerged as a promising strategy for reversing endocrine resistance through epigenetic modulation. In this article, Dr. Peifen Fu of The First Affiliated Hospital, Zhejiang University School of Medicine, discusses the underlying biology of endocrine resistance in advanced HR+ breast cancer and highlights the therapeutic potential of the novel HDACi, entinostat.

As breast cancer continues to rank as the most frequently diagnosed cancer among women worldwide, hormone receptor-positive, HER2-negative (HR+/HER2⁻) disease remains its most common subtype. In recent years, combining CDK4/6…

Breast cancer remains the leading malignancy threatening women’s health worldwide. Among its subtypes, hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer is the most common and typically has a better prognosis, having now entered the era of chronic disease management. In the context of long-term, whole-course management—often spanning over a decade—the concept of “patient-centered care” has become central to clinical practice. Reducing the frequency of medication through long-acting therapies can significantly improve the patient experience, enhance quality of life, and boost adherence.

On March 13, 2025, the "2025 St. Gallen Breast Cancer Conference (SGBCC) Best Poster Awards" were grandly announced. A total of 482 posters were accepted for this year's SGBCC

The 19th St. Gallen  Breast Cancer Conference (SGBCC) took place in Vienna, Austria, from March 12 to 15, 2025. As one of the most prestigious biennial academic events in breast cancer research, SGBCC gathers leading global experts to discuss evolving treatment strategies for early breast cancer, voting on recommendations that shape clinical practice. Notably, this year’s SGBCC will feature a China-focused session, marking a significant milestone. Additionally, Prof. Benlong Yang from Fudan University Shanghai Cancer Center has been named SGBCC’s “Youth Education Ambassador” and “Social Media Ambassador.” This marks the first time a Chinese expert has been awarded such distinctions at SGBCC.

Published in Neuro-Oncology on July 4, 2024, the final analysis from the phase II TUXEDO-1 trial confirms the strong intracranial and systemic efficacy of trastuzumab deruxtecan (T-DXd) in patients with…

In their recent Gastroenterology editorial, Dr. Audrey H. Calderwood (Dartmouth-Hitchcock Medical Center) and Dr. Theodore R. Levin (Kaiser Permanente) raise a compelling question: can fecal immunochemical testing (FIT) be used beyond colorectal cancer (CRC) screening — to guide colonoscopy decisions in patients with GI symptoms?

At the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Kefeng Ding from The Second Affiliated Hospital  Zhejiang University School of Medicine presented innovative advancements in laparoscopic ileocecal-sparing hemicolectomy (LISH) for right-sided colon cancer, highlighting its potential to balance oncologic radicality with functional preservation. His insights provide valuable guidance for clinical practice, promoting precision surgery and organ function preservation in colorectal cancer treatment. Oncology Frontier presents key highlights from his lecture.